| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Prostate Specific Antigen, Total - Medicare Screening
MessageThis test should be ordered for screening purposes for Medicare patients only.
Test Code
2611
Alias/See Also
PSA Screening
Preferred Specimen
One 4 mL serum separator tube or plasma separator tube. Also acceptable: plain red, green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Minimum Volume
1 mL serum or plasma, frozen. (Min: 0.5 mL)
Transport Temperature
1 mL serum or plasma, frozen. (Min: 0.5 mL)
Specimen Stability
Ambient: 8 hours; Refrigerated: 5 days; Frozen: 6 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolyzed samples.
Methodology
Electrochemiluminescent Immunoassay
Setup Schedule
Sun-Sat
Report Available
Within 24 hours
Clinical Significance
The Roche Modular E170 PSA method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche Modular E170 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche Modular E170 PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
